The Prevalence and Incidence of Axial and Peripheral Spondyloarthritis in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis, Journal of Crohn's and Colitis, p.199, 2016. ,
DOI : 10.1093/ecco-jcc/jjw199
Extraintestinal Manifestations of Inflammatory Bowel Disease Inflamm Bowel Dis, pp.1982-92, 2015. ,
Ocular manifestations of inflammatory bowel disease, Current Opinion in Ophthalmology, vol.27, issue.6, pp.552-560, 2016. ,
DOI : 10.1097/ICU.0000000000000310
Cutaneous manifestations in inflammatory bowel disease: a single institutional study of non-neoplastic biopsies over 13 years, Journal of Cutaneous Pathology, vol.105, issue.11, pp.946-955, 2016. ,
DOI : 10.1038/ajg.2010.124
Hepatic manifestations of inflammatory bowel diseases, Liver International, vol.19, issue.5 Suppl ,
DOI : 10.3748/wjg.v19.i42.7327
Li HJ 1 , Zhang CQ 1 . Pulmonary manifestations of Crohn's disease, World J Gastroenterol Jan, vol.720, issue.1 11, pp.133-174, 2014. ,
Inflammatory bowel disease on the risk of acute pancreatitis: A population-based cohort study, Journal of Gastroenterology and Hepatology, vol.15, issue.4, pp.782-789 ,
DOI : 10.1002/ibd.20898
Acute peritonitis complicating Crohn's disease: epidemiologic and physiopathological characteristics, Tunis Med. Feb, vol.89, issue.2, pp.198-201, 2011. ,
Psoas abscess as the initial manifestation of Crohn's disease, 2009. ,
Prevalence and Risk Factors of Acute Lower Gastrointestinal Bleeding in Crohn Disease, Medicine, vol.94, issue.19, p.2015 ,
DOI : 10.1097/MD.0000000000000804
Epidemiology of inflammatory bowel disease, Gastroenterology Clinics of North America, vol.31, issue.1, pp.1-20, 2002. ,
DOI : 10.1016/S0889-8553(01)00002-4
Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD)., Gut, vol.39, issue.5, pp.690-97, 1996. ,
DOI : 10.1136/gut.39.5.690
Geographical variations of inflammatory bowel disease in France: A study based on national health insurance data, Inflammatory Bowel Diseases, vol.12, issue.3, pp.218-244, 2006. ,
DOI : 10.1097/01.MIB.0000206540.38834.8c
URL : https://hal.archives-ouvertes.fr/hal-00466309
Oral Crohn Disease, Archives of Dermatology, vol.135, issue.4, 1999. ,
DOI : 10.1001/archderm.135.4.439
URL : http://archderm.jamanetwork.com/data/journals/derm/11685/dob8032.pdf
Esophagogastroduodenal localizations of Crohn's disease are frequent, Gastroenterol Clin Biol, vol.10, pp.8-9549, 1986. ,
Long-Term Clinical Behavior of Jejunoileal Involvement in Crohn???s Disease, Canadian Journal of Gastroenterology, vol.19, issue.9, pp.575-583, 2005. ,
DOI : 10.1155/2005/647459
Crohn's Disease of the Colon, Rectum, and Anus Surg Clin North Am, pp.1195-210, 2015. ,
The impact of perianal disease in young patients with inflammatory bowel disease, International Journal of Colorectal Disease, vol.103, issue.2, pp.1275-1284, 2015. ,
DOI : 10.1111/j.1572-0241.2008.02212.x
Incidence and Prevalence of Ulcerative Colitis in Copenhagen County from 1962 to 1987, Scandinavian Journal of Gastroenterology, vol.26, issue.158, pp.1247-56, 1991. ,
DOI : 10.1136/gut.26.2.158
Inflammatory bowel disease related innate immunity and adaptive immunity, Am J Transl Res Jun, vol.158, issue.26, pp.2490-2497, 2016. ,
Influence of environmental factors in the development of inflammatory bowel diseases, World Journal of Gastrointestinal Pharmacology and Therapeutics, vol.7, issue.1, pp.112-137 ,
DOI : 10.4292/wjgpt.v7.i1.112
Environmental risk factors for inflammatory bowel diseases: Evidence based literature review, World Journal of Gastroenterology, vol.22, issue.27, pp.6296-317, 2016. ,
DOI : 10.1016/j.cell.2012.02.005
URL : http://doi.org/10.3748/wjg.v22.i27.6296
Exposure to Ambient Air Pollution and the Risk of Inflammatory Bowel Disease: A European Nested Case???Control Study, Digestive Diseases and Sciences, vol.47, issue.10, pp.2963-71, 2016. ,
DOI : 10.1021/es4008849
Tu1104 Cigarette Smoking Adversely Affects Disease Activity and Disease-Specific Quality of Life in Patients With Crohn's Disease (CD) Evaluated At Tertiary Referral Center, Gastroenterology, vol.144, issue.5, pp.307-310, 2016. ,
DOI : 10.1016/S0016-5085(13)62820-6
The ACCURE-trial: the effect of appendectomy on the clinical course of ulcerative colitis, a randomised international multicenter trial (NTR2883) and the ACCURE-UK trial: a randomised external pilot trial (ISRCTN56523019), BMC Surgery, vol.10, issue.1, pp.30-40, 2015. ,
DOI : 10.1111/j.1463-1318.2008.01477.x
Van Domselaar G 1 , Bernstein CN 2 . The Gut Microbiota in Immune- Mediated Inflammatory Diseases. Front Microbiol, Jul, vol.117, 2016. ,
Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease, Inflammatory Bowel Diseases, vol.12, issue.6, 2006. ,
DOI : 10.1097/00054725-200606000-00013
and Christoph Beglinger The role and utility of faecal markers in inflammatory bowel disease Therap Adv Gastroenterol, pp.23-36, 2015. ,
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis, Journal of Crohn's and Colitis, vol.6, issue.10, 2012. ,
DOI : 10.1016/j.crohns.2012.09.003
Endoscopic Diagnosis and Differentiation of Inflammatory Bowel Disease. Clin Endosc, 2016. ,
Current role of capsule endoscopy in Crohn???s disease, World Journal of Gastrointestinal Endoscopy, vol.8, issue.17, pp.572-83, 2016. ,
DOI : 10.4253/wjge.v8.i17.572
Rath T 1 , Neumann H Advanced gastrointestinal endoscopic imaging for inflammatory bowel diseases, World J Gastroenterol, vol.22, issue.3, 2016. ,
DOI : 10.3748/wjg.v22.i3.1246
URL : http://doi.org/10.3748/wjg.v22.i3.1246
Endoscopic scoring indices for evaluation of disease activity in Crohn's disease. Cochrane Database Syst Rev, 2016. ,
Clinical and pathological analysis of colonic Crohn's disease, including a subgroup with ulcerative colitis-like features Modern Pathology, pp.295-307, 2011. ,
Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America, J Pediatr Gastroenterol Nutr, vol.44, issue.5, pp.653-74, 2007. ,
Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative Colitis, New England Journal of Medicine, vol.317, issue.26, pp.1625-1634, 1987. ,
DOI : 10.1056/NEJM198712243172603
Budesonide for induction of remission in Crohn's disease. Cochrane Database Syst Rev, 2015. ,
1 Medical Management of Crohn's Disease Clin Colon Rectal Surg, pp.269-281, 2007. ,
Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev, 2009. ,
Cyclosporine in Severe Ulcerative Colitis Refractory to Steroid Therapy, New England Journal of Medicine, vol.330, issue.26, pp.1841-1846, 1994. ,
DOI : 10.1056/NEJM199406303302601
Methotrexate in ulcerative colitis: A Spanish multicentric study on clinical use and efficacy, Journal of Crohn's and Colitis, vol.5, issue.5, pp.397-401, 2011. ,
DOI : 10.1016/j.crohns.2011.03.012
Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis, Gastroenterology, vol.142, issue.2, pp.257-65, 2011. ,
DOI : 10.1053/j.gastro.2011.10.032
A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor ?? for Crohn's Disease, New England Journal of Medicine, vol.337, issue.15, pp.1029-1064, 1997. ,
DOI : 10.1056/NEJM199710093371502
PURSUIT-Maintenance Study Group Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis, Gastroenterology, vol.146, issue.2 3 31, 2013. ,
Thiopurine Metabolism in the Era of Combotherapy, Inflammatory Bowel Diseases, vol.22, issue.6, pp.1496-501 ,
DOI : 10.1097/MIB.0000000000000737
The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 J Pharmacol Exp Ther, pp.864-75, 2009. ,
Sandborn W 3 , et al. The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut ,
European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease, Journal of Crohn's and Colitis, vol.3, issue.2, pp.47-91, 2009. ,
DOI : 10.1016/j.crohns.2009.02.010
Saro C 3 et al. Risk factors for tuberculosis in inflammatory bowel disease: anti-tumor necrosis factor and hospitalization, Rev Esp Enferm Dig, vol.2108, issue.29, pp.541-550, 2016. ,
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target, The American Journal of Gastroenterology, vol.107, issue.9, pp.1324-1338, 2015. ,
DOI : 10.1038/ajg.2012.117
URL : https://hal.archives-ouvertes.fr/hal-01191653
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis, New England Journal of Medicine, vol.369, issue.8, pp.699-710, 2013. ,
DOI : 10.1056/NEJMoa1215734
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease, New England Journal of Medicine, vol.369, issue.8, pp.711-721, 2013. ,
DOI : 10.1056/NEJMoa1215739
Effects of Vedolizumab Induction Therapy for Patients With Crohn???s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed, Gastroenterology, vol.147, issue.3, pp.618-627, 2014. ,
DOI : 10.1053/j.gastro.2014.05.008
A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITY, The Lancet, vol.315, issue.8167, p.514, 1980. ,
DOI : 10.1016/S0140-6736(80)92767-1
Meta-analysis of the effectiveness and safety of vedolizumab for ulcerative colitis, World Journal of Gastroenterology, vol.21, issue.20, pp.6352-6360, 2015. ,
DOI : 10.2147/BTT.S30416
on the behalf of the OBSERV-IBD study group and the GETAID, Effectiveness and Safety of Vedolizumab Induction Therapy for Patients with Inflammatory Bowel Disease, Clinical Gastroenterology and Hepatology ,
Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients, Inflammatory Bowel Diseases, vol.21, issue.12, 2015. ,
DOI : 10.1097/MIB.0000000000000561
Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to TNF Antagonist Clin Gastroenterol Hepatol, pp.1542-356530655, 2016. ,
Long-term Clinical Experience with Vedolizumab in Patients with Inflammatory Bowel Disease, Inflammatory Bowel Diseases, vol.19, issue.8, pp.1691-1700 ,
DOI : 10.1097/MIB.0b013e318281f538
Long-term Efficacy of Vedolizumab for Crohn???s Disease, Journal of Crohn's and Colitis ,
DOI : 10.1093/ecco-jcc/jjw176
Long-term Efficacy of Vedolizumab for Ulcerative Colitis J Crohns Colitis, p.177, 2016. ,
Endoscopic Evaluation of Crohn's Disease Activity comparison of the CDEIS and the SES-CD Inflamm Bowel Dis, pp.2131-2137, 2010. ,
Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS), Gut, vol.61, issue.4, pp.535-577, 2012. ,
DOI : 10.1136/gutjnl-2011-300486
Hartke J. 2 , Chilukuri P. et al. Predictors of clinical and endoscopic response with vedolizumab for the treatment of moderately-severely active ulcerative colitis: results from the US VICTORY consortium ,
Lasch Effects of vedolizumab on health-related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial ,
Integrin, New England Journal of Medicine, vol.352, issue.24, pp.2499-507, 2005. ,
DOI : 10.1056/NEJMoa042982
Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease, Expert Review of Clinical Immunology, vol.6, issue.4, pp.567-572, 2010. ,
DOI : 10.2165/00063030-200822040-00005
Uma Mahadevan; Severine Vermeire; Brihad Abhyankar; Karen Lasch Vedolizumab Exposure in Pregnancy : Outcomes From Clinical Studies in Inflammatory Bowel Disease ,
Colombel 2 , R. Panaccione 3 , K. Lasch 4 , R. Mody 5 , A. Green 6 , B. Abhyankar 7 Deep remission as a predictor of clinical outcomes in vedolizumabtreated patients with ulcerative colitis ,
for the CERTIFI Study Group: Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease ,
Discovery and mechanism of ustekinumab, a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders MAbs, pp.535-545, 2011. ,
Panes J 3 , Vranic I 4 Niezychowski W 6 ; Study A3921043 Investigators. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease, Clin Gastroenterol Hepatol, vol.12, issue.2 59, 2014. ,
Grinspan A 1 . Fecal Microbiota Transplantation for Inflammatory Bowel Disease, Gastroenterol Hepatol, vol.12, issue.6, pp.374-383 ,
Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis, New England Journal of Medicine, vol.374, issue.18, pp.1754-62, 2016. ,
DOI : 10.1056/NEJMoa1513248